Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leukemia
Cancer Researchers at Manhattan-based St. Vincent's Comprehensive Cancer Center Discover Genes That Can Determine How Patients Respond to Pre-Leukemia Drug
April 8th, 2008
A team of cancer researchers at Manhattan-based St. Vincent's Comprehensive Cancer Center, in partnership with the Broad Institute of MIT and the Dana Farber Cancer Institute in Boston, has identified 30 red cell-related genes which determine the effectiveness of using the drug Revlimid(R) (lenalidomide) on patients with pre-leukemia, known as Myelodysplastic Syndrome (MDS). The discovery was recently reported in the on-line journal PLoS Medicine (medicine.plosjournals.org). Nearly 20,000 Americans are diagnosed annually with MDS. While most are men over 65 years old, women, young people and children also develop MDS. The causes have not been...
Source: Cancer Weekly (2008-04-08)
|
